Argus Research Upgrades Silk Road Medical to Buy, Announces $24 Price Target
Portfolio Pulse from Benzinga Newsdesk
Argus Research analyst Steve Silver upgrades Silk Road Medical (NASDAQ:SILK) from Hold to Buy and sets a $24 price target.

March 07, 2024 | 3:43 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Silk Road Medical was upgraded by Argus Research from Hold to Buy with a new price target of $24.
Upgrades by research firms, especially with a significant price target increase, typically lead to positive short-term price movements as they reflect a positive outlook on the company's future performance.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100